Literature DB >> 12689676

Involvement of vacuolar H+ -ATPase in incorporation of risedronate into osteoclasts.

M Takami1, K Suda, T Sahara, K Itoh, K Nagai, T Sasaki, N Udagawa, N Takahashi.   

Abstract

Although osteoclasts incorporate bisphosphonates during bone resorption, the mechanism of this incorporation by osteoclasts is not known. We previously reported that bisphosphonates disrupt the actin rings (clear zones) formed in normal osteoclasts, but did not disrupt actin rings in osteoclasts derived from osteosclerotic oc/oc mice, which have a defect in the gene encoding vacuolar H(+)-ATPase (V-ATPase). The present study showed that V-ATPase is directly involved in the incorporation of risedronate, a nitrogen containing bisphosphonate, into osteoclasts. Treatment of osteoclasts with risedronate disrupted actin rings and inhibited pit formation by osteoclasts on dentine slices. Bafilomycin A(1), a V-ATPase inhibitor, inhibited the pit-forming activity of osteoclasts but did not disrupt actin rings. Risedronate failed to disrupt actin rings in the presence of bafilomycin A(1). E-64, a lysosomal cysteine proteinase inhibitor, showed no inhibitory effect on the demineralization of dentine by osteoclasts but inhibited the digestion of dentine matrix proteins without disrupting actin rings. Risedronate disrupted actin rings even in the presence of E-64. Treatment of osteoclasts placed on plastic plates with risedronate also disrupted actin rings. Bafilomycin A(1) but not E64 prevented the disruption of actin rings in osteoclasts treated with risedronate on plastic plates. Inhibition of V-ATPase with bafilomycin A(1) also prevented disruption of actin rings by etidronate, a non-nitrogen-containing bisphosphonate. These results suggest that V-ATPase induced acidification beneath the ruffled borders of osteoclasts and subsequent bone demineralization triggers the incorporation of both nitrogen-containing and non-nitrogen-containing bisphosphonates into osteoclasts.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12689676     DOI: 10.1016/s8756-3282(03)00024-3

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  6 in total

Review 1.  Regulation of osteoclast polarization.

Authors:  Naoyuki Takahashi; Sadakazu Ejiri; Shigeru Yanagisawa; Hidehiro Ozawa
Journal:  Odontology       Date:  2007-07-25       Impact factor: 2.634

2.  Minodronic acid induces morphological changes in osteoclasts at bone resorption sites and reaches a level required for antagonism of purinergic P2X2/3 receptors.

Authors:  Makoto Tanaka; Akihiro Hosoya; Hiroshi Mori; Ryoji Kayasuga; Hiroaki Nakamura; Hidehiro Ozawa
Journal:  J Bone Miner Metab       Date:  2017-02-27       Impact factor: 2.626

3.  Mechanistic insights into protonation state as a critical factor in hFPPS enzyme inhibition.

Authors:  David Fernández; Joaquin Ortega-Castro; Laura Mariño; Joan Perelló; Juan Frau
Journal:  J Comput Aided Mol Des       Date:  2015-06-17       Impact factor: 3.686

4.  Zoledronate promotes inflammatory cytokine expression in human CD14-positive monocytes among peripheral mononuclear cells in the presence of γδ T cells.

Authors:  Reiko Takimoto; Tetsuo Suzawa; Atsushi Yamada; Kiyohito Sasa; Yoichi Miyamoto; Kentaro Yoshimura; Yuji Sasama; Motohiro Tanaka; Mitsuhiro Kinoshita; Kaori Ikezaki; Makoto Ichikawa; Matsuo Yamamoto; Tatsuo Shirota; Ryutaro Kamijo
Journal:  Immunology       Date:  2020-11-23       Impact factor: 7.397

5.  Beclin1 Modulates Bone Homeostasis by Regulating Osteoclast and Chondrocyte Differentiation.

Authors:  Atsushi Arai; Sol Kim; Vadim Goldshteyn; Terresa Kim; No-Hee Park; Cun-Yu Wang; Reuben H Kim
Journal:  J Bone Miner Res       Date:  2019-07-30       Impact factor: 6.390

6.  Induction of creatine kinase release from cultured osteoclasts via the pharmacological action of aminobisphosphonates.

Authors:  Makoto Tanaka; Hiroshi Mori; Ryoji Kayasuga; Kazuhito Kawabata
Journal:  Springerplus       Date:  2015-02-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.